Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …
被引用次数：145 相关文章

[引用][C] Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen, I Lingvay… - Diabetes, Obesity and …, 2020 - cir.nii.ac.jp
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes
across varying cardiovascular risk | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain… - Diabetes …, 2020 - utsouthwestern.elsevierpure.com
Aim: To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.

M Husain, SC Bain, OK Jeppesen, I Lingvay… - Diabetes, Obesity & …, 2020 - europepmc.org
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …
[HTML] nih.gov

[HTML][HTML] Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity & …, 2020 - ncbi.nlm.nih.gov
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen… - Diabetes, obesity & …, 2020 - pubmed.ncbi.nlm.nih.gov
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.

M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity & …, 2020 - search.ebscohost.com
Aim: To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity …, 2020 - research.regionh.dk
AIM: To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.

M Husain, SC Bain, OK Jeppesen, I Lingvay… - Diabetes, Obesity & …, 2020 - europepmc.org
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …